# The One Place People Felt Better

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-11-01

Canonical page: https://glpwatchdog.org/research/the-one-place-people-felt-better

> No obesity drug improved general quality of life across 43 trials. Both heart failure trials produced large symptom improvements. Those findings are not in conflict, because the heart failure trials used a disease-specific symptom measure.

## Key points

- Symptom score +7.8 (semaglutide) and +6.9 (tirzepatide), both above the ~5 points patients notice.
- Resolves an apparent conflict: general health surveys found nothing; a DISEASE-SPECIFIC one found this.
- STEP-HFpEF halved serious adverse events: 13.3% vs 26.7%.
- SUMMIT's composite is carried by heart-failure events (HR 0.54); CV DEATHS were 8 vs 5, HR 1.58.
- Thirteen deaths in total are too few to establish anything either way.
- 6-minute walk +20.3 m, below the ~30 m usually called clinically important.

Across 43 trials and 45,663 participants, no obesity drug improved quality of life on average [enough for patients to notice](https://glpwatchdog.org/research/real-and-below-the-threshold). In two trials of heart failure with preserved ejection fraction, both drugs produced large improvements on a symptom score.[1][2] Those findings look contradictory but are not. The difference lies in which question each questionnaire asks.

## What these trials measured

Heart failure with preserved ejection fraction is a condition where the heart pumps normally but cannot fill properly, and in its obesity-related form it produces breathlessness, exhaustion and a shrinking radius of what someone can do. Until recently nothing was approved to treat it.

Both trials used the Kansas City Cardiomyopathy Questionnaire as a primary endpoint. It is a score from 0 to 100 built specifically from the symptoms and physical limitations of heart failure. Higher is better, and a difference of roughly five points is generally treated as the smallest a patient would notice.

*Two separate randomized trials. Each is compared against its own placebo arm, not against the other.*

|   | STEP-HFpEF[1] | SUMMIT[2] |
| --- | --- | --- |
| Drug | Semaglutide 2.4 mg | Tirzepatide up to 15 mg |
| Participants | 529 | 731 |
| **Symptom score difference** | **+7.8** (95% CI 4.8–10.9) | **+6.9** (3.3–10.6) |
| Weight change | −13.3% vs −2.6% | — |
| 6-minute walk distance | +20.3 m (8.6–32.1) | — |
| Inflammation (CRP) | −43.5% vs −7.3% | — |
| Serious adverse events | **13.3% vs 26.7%** | — |
| Death or worsening heart failure | — | 9.9% vs 15.3%, HR 0.62 (0.41–0.95) |

Both symptom differences clear the threshold for a change patients notice, and both were highly significant. In [STEP-HFpEF](https://glpwatchdog.org/research/trials/step-hfpef) one more row stands out: **serious adverse events occurred half as often on the drug** (13.3% against 26.7%), and in this population those are largely heart failure events.

> **One number that falls short.** The 6-minute walk distance improved by 20.3 meters against placebo, and the difference usually treated as clinically important is around 30. It is a real, statistically solid improvement, but it sits below the threshold people generally use. The symptom score is the stronger finding of the two.

## Why this is not a contradiction

Elsewhere we have reported, twice, that these drugs fall short on broad quality-of-life measures. In [a review of 262 trials](https://glpwatchdog.org/research/what-262-trials-say-together), no agent cleared the threshold in the 43 that measured quality of life, and in [the head-to-head trial](https://glpwatchdog.org/research/the-mental-health-score-that-did-not-move) the mental component did not move in either arm.

> **Those studies looked at broad quality of life. These used a disease-specific questionnaire.** A general instrument asks how your life is going, and averages across everything that bears on that. The Kansas City questionnaire asks how breathless you are climbing stairs, how often swelling wakes you, how far your heart failure has narrowed what you do. In a disease the drug treats, the specific instrument finds what the general one dilutes to nothing.

That resolves the apparent conflict and narrows the claim in a useful way. There is no good evidence that these drugs make people feel better in general. There is good evidence that in obesity-related heart failure they relieve the symptoms of that condition. That is a narrower claim, and a better-supported one.

> Feeling better in general and feeling less breathless are different questions, and only one of them has been answered yes.

## Decompose the composite

[SUMMIT](https://glpwatchdog.org/research/trials/summit)’s headline outcome was a composite of cardiovascular death *or* a worsening heart failure event, and it came in at a hazard ratio of 0.62. Composites should always be taken apart, and this one is instructive when you do.

*SUMMIT’s composite endpoint, by component.[2]*

| Component | Tirzepatide | Placebo | Hazard ratio |
| --- | --- | --- | --- |
| Worsening heart failure | 29 (8.0%) | 52 (14.2%) | **0.54 (0.34–0.85)** |
| **Cardiovascular death** | **8 (2.2%)** | **5 (1.4%)** | **1.58 (0.52–4.83)** |

The benefit is carried entirely by worsening heart failure events. The mortality component points the *other* way, with more cardiovascular deaths on the drug than on placebo.

> **Thirteen deaths in total, and a confidence interval running from 0.52 to 4.83.** That establishes nothing in either direction, and it would be as wrong to call this a mortality signal as to ignore it. What it does show is that a composite reported alone can conceal a hard component moving against the drug. The general problem is set out in [a composite is only its components](https://glpwatchdog.org/research/a-composite-is-only-its-components).

Adverse events led 6.3% of the tirzepatide group to stop, against 1.4% on placebo. The events were mainly gastrointestinal, as everywhere in this class.

## What these two trials do not do

- **They do not compare the drugs.** Two separate trials, different populations, different placebo arms. A comparison does exist; it is observational, and it found [no meaningful difference between them](https://glpwatchdog.org/research/how-to-trust-an-observational-study).
- **They enrolled people with obesity** (a BMI of 30 or more), so they speak to obesity-related heart failure specifically.
- **STEP-HFpEF ran 52 weeks**; SUMMIT followed people a median of 104. Neither is long for a chronic condition.
- **Each was funded by the maker of its drug**, Novo Nordisk and Eli Lilly respectively.

## Frequently asked questions

### Do GLP-1 drugs help heart failure with preserved ejection fraction?

Both randomized trials found large improvements in heart failure symptoms: 7.8 points on the Kansas City questionnaire with semaglutide and 6.9 with tirzepatide, where about five points is the smallest difference patients notice. Tirzepatide also reduced a composite of cardiovascular death or worsening heart failure.

### Other studies say these drugs do not improve quality of life. Which is right?

Both. Those studies looked at broad quality of life, which averages across everything in a life. These used a questionnaire built from heart failure symptoms specifically. In a disease the drug treats, a specific instrument finds what a general one dilutes.

### Did tirzepatide reduce deaths?

No. Its composite benefit came entirely from fewer worsening heart failure events. Cardiovascular deaths were 8 on the drug against 5 on placebo. That is thirteen events in total, with a confidence interval far too wide to establish anything either way.

### What was the most striking safety finding?

In STEP-HFpEF, serious adverse events occurred in 13.3% on semaglutide against 26.7% on placebo, or half as often. In this population those are largely heart failure events.

### Which drug is better for this?

These two trials cannot answer that, being separate studies with their own populations and placebo arms. An observational comparison of the two found no meaningful difference on hard outcomes.

## References

1. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. The New England Journal of Medicine. 2023. PMID: 37622681. https://pubmed.ncbi.nlm.nih.gov/37622681/
2. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. The New England Journal of Medicine. 2025. PMID: 39555826. https://pubmed.ncbi.nlm.nih.gov/39555826/

---

Cite as: GLP Watchdog, Nora Bissett, "The One Place People Felt Better", published 2026-08-20, updated 2026-11-01. https://glpwatchdog.org/research/the-one-place-people-felt-better

Canonical HTML page: https://glpwatchdog.org/research/the-one-place-people-felt-better

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
